Journal of psychiatric research · 2026
Medicinal plants for obsessive-compulsive disorder: A review of phytotherapeutic approaches.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
S Devaraja Dravida Pandiyan, Jeyabalan Srikanth, Subramaniyan Vetriselvan, Balu Anbarasan, Wong Ling Shing, Sekar Mahendran, Ashok Chetan
Аннотация
BACKGROUND: Obsessive-compulsive disorder (OCD) is a chronic psychiatric condition characterized by intrusive thoughts and repetitive behaviors that impair functioning. Although selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy are first-line treatments, 40-60% of patients achieve only partial remission, with persistent symptoms and adverse effects. This highlights the need for alternative approaches such as phytotherapy, which has shown potential neuroprotective and neurotransmitter-modulating properties.
METHODS: A structured narrative review with a systematic search was conducted across PubMed, Scopus, Web of Science, and Google Scholar up to April 2025. Studies evaluating medicinal plants or phytochemicals in OCD or OCD-like behavior were included. Both preclinical in vivo and human studies were assessed. A total of 26 studies (14 preclinical, 12 clinical) were included and appraised using a multi-domain quality framework and evidence hierarchy.
RESULTS: Preclinical studies indicated that several plant-derived compounds influence serotonergic, dopaminergic, and GABAergic systems and reduce OCD-like behaviors. However, most relied on non-specific models such as marble-burying, limiting interpretability. Clinical evidence was limited, with few randomized controlled trials and several low-quality or observational studies. While some interventions showed symptom improvement, methodological weaknesses and small sample sizes reduced reliability.
DISCUSSION: Current evidence does not support clinical recommendations for phytotherapy in OCD. Findings remain preliminary and hypothesis-generating. Future research should focus on well-designed clinical trials, standardized formulations, and translationally valid models to establish efficacy and safety.
METHODS: A structured narrative review with a systematic search was conducted across PubMed, Scopus, Web of Science, and Google Scholar up to April 2025. Studies evaluating medicinal plants or phytochemicals in OCD or OCD-like behavior were included. Both preclinical in vivo and human studies were assessed. A total of 26 studies (14 preclinical, 12 clinical) were included and appraised using a multi-domain quality framework and evidence hierarchy.
RESULTS: Preclinical studies indicated that several plant-derived compounds influence serotonergic, dopaminergic, and GABAergic systems and reduce OCD-like behaviors. However, most relied on non-specific models such as marble-burying, limiting interpretability. Clinical evidence was limited, with few randomized controlled trials and several low-quality or observational studies. While some interventions showed symptom improvement, methodological weaknesses and small sample sizes reduced reliability.
DISCUSSION: Current evidence does not support clinical recommendations for phytotherapy in OCD. Findings remain preliminary and hypothesis-generating. Future research should focus on well-designed clinical trials, standardized formulations, and translationally valid models to establish efficacy and safety.